KR20250161038A - 티카그렐러 활성을 반전시키는 방법 - Google Patents
티카그렐러 활성을 반전시키는 방법Info
- Publication number
- KR20250161038A KR20250161038A KR1020257035868A KR20257035868A KR20250161038A KR 20250161038 A KR20250161038 A KR 20250161038A KR 1020257035868 A KR1020257035868 A KR 1020257035868A KR 20257035868 A KR20257035868 A KR 20257035868A KR 20250161038 A KR20250161038 A KR 20250161038A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- ticagrelor
- pharmaceutical composition
- hours
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733892P | 2018-09-20 | 2018-09-20 | |
| US62/733,892 | 2018-09-20 | ||
| US201962806225P | 2019-02-15 | 2019-02-15 | |
| US62/806,225 | 2019-02-15 | ||
| US201962836373P | 2019-04-19 | 2019-04-19 | |
| US62/836,373 | 2019-04-19 | ||
| KR1020217011614A KR102880762B1 (ko) | 2018-09-20 | 2019-09-20 | 티카그렐러 활성을 반전시키는 방법 |
| PCT/US2019/052173 WO2020061465A1 (en) | 2018-09-20 | 2019-09-20 | Methods of reversing ticagrelor activity |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011614A Division KR102880762B1 (ko) | 2018-09-20 | 2019-09-20 | 티카그렐러 활성을 반전시키는 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250161038A true KR20250161038A (ko) | 2025-11-14 |
Family
ID=69887913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011614A Active KR102880762B1 (ko) | 2018-09-20 | 2019-09-20 | 티카그렐러 활성을 반전시키는 방법 |
| KR1020257035868A Pending KR20250161038A (ko) | 2018-09-20 | 2019-09-20 | 티카그렐러 활성을 반전시키는 방법 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011614A Active KR102880762B1 (ko) | 2018-09-20 | 2019-09-20 | 티카그렐러 활성을 반전시키는 방법 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP4653465A3 (https=) |
| JP (2) | JP7478975B2 (https=) |
| KR (2) | KR102880762B1 (https=) |
| CN (1) | CN113194821B (https=) |
| AU (1) | AU2019342755B2 (https=) |
| CA (1) | CA3113654A1 (https=) |
| DK (1) | DK3852617T3 (https=) |
| ES (1) | ES3042247T3 (https=) |
| FI (1) | FI3852617T3 (https=) |
| MX (1) | MX2021003298A (https=) |
| PL (1) | PL3852617T3 (https=) |
| WO (1) | WO2020061465A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6799530B2 (ja) | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| KR102880762B1 (ko) * | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
| EP4337253A4 (en) * | 2021-05-10 | 2025-03-19 | Sfj Pharmaceuticals X, Ltd. | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody |
| KR102952285B1 (ko) | 2021-07-13 | 2026-04-13 | 주식회사 엘지에너지솔루션 | 전지의 용접 상태 검사 방법 |
| WO2026019858A1 (en) * | 2024-07-16 | 2026-01-22 | SFJ Pharma X, Inc. | Methods of reversing ticagrelor activity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03154867A (ja) * | 1989-11-13 | 1991-07-02 | Teijin Ltd | １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット |
| US9101642B2 (en) | 2011-06-01 | 2015-08-11 | Astrazeneca Ab | Ticagrelor co-crystal |
| JP2016502526A (ja) * | 2012-11-16 | 2016-01-28 | ノバルティス アーゲー | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
| WO2016033424A1 (en) * | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| JP6799530B2 (ja) * | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| AU2016210973B2 (en) * | 2015-01-27 | 2019-02-14 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
| KR101916956B1 (ko) * | 2016-12-13 | 2018-11-08 | 보령제약 주식회사 | 티카그렐러의 신규한 고체 형태 및 이의 제조방법 |
| IL267519B2 (en) * | 2016-12-23 | 2025-04-01 | Novartis Ag | Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease |
| BR112019018022A2 (pt) | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| KR102880762B1 (ko) * | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
-
2019
- 2019-09-20 KR KR1020217011614A patent/KR102880762B1/ko active Active
- 2019-09-20 ES ES19863329T patent/ES3042247T3/es active Active
- 2019-09-20 PL PL19863329.9T patent/PL3852617T3/pl unknown
- 2019-09-20 DK DK19863329.9T patent/DK3852617T3/da active
- 2019-09-20 CA CA3113654A patent/CA3113654A1/en active Pending
- 2019-09-20 KR KR1020257035868A patent/KR20250161038A/ko active Pending
- 2019-09-20 MX MX2021003298A patent/MX2021003298A/es unknown
- 2019-09-20 CN CN201980075991.0A patent/CN113194821B/zh active Active
- 2019-09-20 FI FIEP19863329.9T patent/FI3852617T3/fi active
- 2019-09-20 WO PCT/US2019/052173 patent/WO2020061465A1/en not_active Ceased
- 2019-09-20 JP JP2021515473A patent/JP7478975B2/ja active Active
- 2019-09-20 AU AU2019342755A patent/AU2019342755B2/en active Active
- 2019-09-20 EP EP25193499.8A patent/EP4653465A3/en active Pending
- 2019-09-20 EP EP19863329.9A patent/EP3852617B1/en active Active
-
2024
- 2024-04-09 JP JP2024062468A patent/JP2024096134A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7478975B2 (ja) | 2024-05-08 |
| DK3852617T3 (da) | 2025-10-20 |
| KR102880762B1 (ko) | 2025-11-03 |
| FI3852617T3 (fi) | 2025-10-21 |
| JP2022501368A (ja) | 2022-01-06 |
| ES3042247T3 (en) | 2025-11-19 |
| US20210347915A1 (en) | 2021-11-11 |
| MX2021003298A (es) | 2021-08-11 |
| WO2020061465A1 (en) | 2020-03-26 |
| PL3852617T3 (pl) | 2026-01-26 |
| CN113194821B (zh) | 2025-07-04 |
| EP3852617B1 (en) | 2025-09-10 |
| CA3113654A1 (en) | 2020-03-26 |
| JP2024096134A (ja) | 2024-07-12 |
| EP3852617A4 (en) | 2022-08-24 |
| KR20210091698A (ko) | 2021-07-22 |
| AU2019342755A1 (en) | 2021-05-06 |
| EP4653465A3 (en) | 2026-01-07 |
| AU2019342755B2 (en) | 2025-12-11 |
| EP4653465A2 (en) | 2025-11-26 |
| CN113194821A (zh) | 2021-07-30 |
| EP3852617A1 (en) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102880762B1 (ko) | 티카그렐러 활성을 반전시키는 방법 | |
| JP6193871B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| KR20190044673A (ko) | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 | |
| EP4488295A2 (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| JP2026048712A (ja) | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン | |
| JP2022501368A5 (https=) | ||
| US20230192895A1 (en) | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody | |
| JP2023507795A5 (https=) | ||
| CN120265653A (zh) | 治疗心血管疾病的方法 | |
| AU2017355613B2 (en) | Treatment regimens | |
| CN111344043A (zh) | 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法 | |
| US12617870B2 (en) | Methods of reversing ticagrelor activity | |
| US20140228316A1 (en) | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | |
| JP2023541249A (ja) | 治療用抗体製剤 | |
| US20200055942A1 (en) | Treatment regimens | |
| US20260022197A1 (en) | Methods of reversing ticagrelor activity | |
| US20250018010A1 (en) | Pharmaceutical composition | |
| JP2021523894A (ja) | カナキヌマブの使用 | |
| HK40120349A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| WO2026072994A1 (en) | Methods for the treatment of cardiovascular disease | |
| AU2024349732A1 (en) | Methods for the treatment of cardiovascular disease | |
| HK40085254A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| HK40058594A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |